Dihydroartemisinin derivatives and the treatment of fibrotic diseases
Patent Information
- Application Number
- HK62026126470
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-19
- Filing Date
- 2026-07-21
- Publication Date
- 2026-09-18
- Estimated Expiration
- 2044-07-17
Abstract
Description
Compounds of formulas PT-1, PT-2, PT-4, PT-13, PT-14, PT-20, PT-23 to PT-25, and PT-27 to PT-30, and their salts, pharmaceutical formulations containing them, and the use of these compounds for the treatment of fibrotic diseases. Abstract
Claims
What is claimed is:
1. A compound of any one of the formulae PT-1, PT-2, PT-4, PT-13, PT-14, PT-20, PT-23 to PT-25, and PT-27 to PT-30:or a salt, especially a pharmaceutically acceptable salt, thereof.
2. The compound of claim 1 that is a compound of any one of the formulae PT-1, PT-2, and PT-4, or a salt, especially a pharmaceutically acceptable salt, thereof.
3. The compound of claim 1 that is a compound of one of the formulae PT- 13, PT- 14, PT-20, PT-23 to PT-25, and PT-27 to PT-30, or a salt, especially a pharmaceutically acceptable salt, thereof.
4. The compound of claim 1 that is a compound of any one of the formulae PT-2, PT- 14, PT-28, and PT-30, or a salt, especially a pharmaceutically acceptable salt, thereof.
5. The compound of claim 1 that is a compound of formula PT- 14 or PT-30, or a salt, especially a pharmaceutically acceptable salt, thereof.
6. The compound of claim 5 that is a compound of formula PT- 14, or a salt, especially a pharmaceutically acceptable salt, thereof.
7. The compound of claim 6 that is a compound of formula PT- 14.
8. The compound of claim 5 that is a compound of formula PT-30, or a salt, especially a pharmaceutically acceptable salt, thereof.
9. The compound of claim 8 that is a compound of formula PT-30.
10. A pharmaceutical formulation for the treatment of a fibrotic disease in a human subject, comprising a therapeutically effective amount of a compound of any one of claims 1 to 9 and a pharmaceutically acceptable excipient.
11. A method of treating a fibrotic disease in a human subject, comprising administering to the human subject a therapeutically effective amount of a compound of any one of claims 1 to 9 or a pharmaceutical formulation of claim 10.
12. The method of claim 11 , where the fibrotic disease is a systemic fibrotic disease.
13. The method of claim 12, where the systemic fibrotic disease is systemic sclerosis, multifocal fibrosclerosis (IgG4-associated fibrosis), nephrogenic systemic fibrosis, or sclerodermatous graft-versus-host disease.
14. The method of claim 11, where the fibrotic disease is an organ- specific fibrotic disease.
15. The method of claim 14, where the organ-specific fibrotic disease is cardiac fibrosis, kidney fibrosis, pulmonary fibrosis, liver and portal vein fibrosis, radiation-induced fibrosis, bladder fibrosis, intestinal fibrosis, pancreatic fibrosis, peritoneal sclerosis, diffuse fasciitis, localized scleroderma, keloids, Dupuytren’s disease, Peyronie’s disease, myelofibrosis, or oral submucous fibrosis.
16. The method of any one of claims 11 to 15, where the amount of the compound administered is 10 mg / day to 600 mg / day; for example, 30 mg / day to 400 mg / day, such as10 mg / day, 30 mg / day, 50 mg / day, lOOmg / day, 200 mg / day, or 400 mg / day.